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INTRODUCTION
“The  purpose  of  medicine  is  to  prevent  disease,  to  decrease  pain  and  to  postpone 
death……….  Technology  has  to  support  these  goals…………  if  not,  it  may  not  serve 
mankind”, Dr.Timothy J Thomas (Consultant Physician, Mayo Clinic) technology.
Of all diseases known to mankind, many are preventable and most can be controlled if 
detected at an early stage.  One such is Acute Kidney Injury (AKI).
Acute  Kidney  Injury  (AKI)  is  responsible  for  3-7%  of  hospitalisation4 and 
approximately 25-30% of patients in intensive care unit4. The mortality rate estimates of AKI 
vary from 25-90%4. The in- hospital mortality of 40-50% and ICU mortality rate of 70-80%4,5 
(western data). Available investigation today have many times been late in detecting AKI and 
have  caused  serious  delay  which  has  caused  considerable  increase  in  mortality  in  patients 
admitted with AKI.
Several biomarkers have been thrown into limelight to be an early predictor of AKI. 
Neutrophil  Gelatinase Associated Lipocalcin(NGAL),  cystatin-C,  Urinary IL – 18(U IL18), 
Kidney Injury Molecule (KIM-I) are some of them1,2,8.
There has been considerable disparity in results of few studies which have used them. 
Some have shown to be promising and others equivocal.
UIL 18 is  one such marker  with varied results.   Previous  studies  demonstrated that 
urinary IL-18 was raised in mouse and human AKI.  But levels to predict early AKI, sensitivity 
and specificity and predictive values have not been clearly defined.  An UIL 18 study was 
carried to know the utility of this biomarker in predicting AKI earlier than now. The platform 
to test this study was chosen to be on patients admitted with snake bite and going in for acute 
kidney injury.
The goal of this study were to determine the association between UIL 18 and AKI and 
the reliability for them to be used as early marker in detecting AKI in comparison with pre 
existing surrogate markers of kidney injury like creatinine and urea. 
AIMS AND OBJECTIVES
1. To assess urinary IL – 18 levels in snake bite patients.
2. To co-relate with established markers of renal failure - urea and creatinine.
3. Early detection of impending renal failure in snake bite patients.
4. To extrapolate the usefulness and applicability in other clinical situations causing 
AKI.
                    
          REVIEW OF LITERATURE
As mentioned before AKI contributes to 40-50% of in-hospital and        70-80% of 
intensive medical care unit (ICU) mortality4 .These figures are predicted to be higher in Asian 
population. These figures tell us the magnitude of disease in itself. 
So, in 2004  in order to bring uniformity across the globe the Acute Dialysis Quality 
Initiative work group set  forth a definition and classification system for acute renal  failure 
(later termed as AKI) described by the acronym RIFLE (Risk ,injury, failure, loss, end stage 
kidney disease). 
Investigators have since applied the RIFLE system to the clinical evaluation of AKI, 
although  it  was  not  originally  intended  for  that  purpose.   AKI  research  increasingly uses 
RIFLE.  For all  practical purposes AKI is defined as 50% rise in creatinine from baseline. 
Researchers  have  used  different  clinical  settings  like  ICU,  contrast  nephropathy,  diabetic 
nephropathy  and  ARDS trial  to  find  early  biomarkers  to  detect  AKI  so  that  considerable 
mortality and morbidity could be alleviated.   The following table shows RIFLE classification 
using GFR and urine output criteria to classify AKI2,4.                 
Stage GFR  Criteria Urine Output 
Criteria
Probability
Risk SCreat  increased × 
1.5
 or 
GFR decreased 
>25%
UO  <0.5 mL/kg/h × 
6 h
Injury SCreat increased × 2
 or 
GFR decreased 
>50%
UO <0.5 mL/kg/h × 
12 h
Failure SCreat increased × 3
or 
GFR decreased 75%
or 
SCreat ≥4 mg/dL; 
acute rise ≥0.5 
mg/dL
UO <0.3 mL/kg/h × 
24 h
(oliguria)
or 
anuria × 12 h
High sensitivity (Risk 
>Injury >Failure)
Loss Persistent acute renal failure: complete 
loss of kidney function >4 wk
ESKD* Complete loss of kidney function >3 mo
High specificity
      
Table: RIFLE classification of AKI (adopted from enephrology)
ESKD - end-stage kidney disease; GFR - glomerular filtration rate
SCreat - serum creatinine; UO - urine output
Patients can be classified by GFR criteria and/or UO criteria. 
The criteria that support the most severe classification should be used. 
The  superimposition  of  acute  on  chronic  failure  is  indicated  with  the  designation 
RIFLE-F C; failure is present in such cases even if the increase in SCreat is less than 3-fold, 
provided that the new SCreat is greater than 4.0 mg/dL and results from an acute increase of at 
least 0.5 mg/dL.
When the failure classification is achieved by UO criteria, the designation of RIFLE-F O 
is used to denote oliguria.
The initial stage, risk, has high sensitivity; more patients will be classified in this mild 
category,  including  some  who  do  not  actually  have  renal  failure.  Progression  through  the 
increasingly  severe  stages  of  RIFLE  is  marked  by  decreasing  sensitivity  and  increasing 
specificity. 
With  improved  classification  and  treatment  modalities,  mortality  due  to  AKI  still 
remains high. This can be attributed to difficulty in early recognition and timely institution of 
treatment as existing markers of renal dysfunction show up when it has already been late in 
most cases. Handful of new markers have showed promise in recent times, to better existing 
biomarkers in this aspect .The  validity of such markers can be assessed with snake bite since it 
forms 15% of AKI occurring in our country10. 
 Although nearly all snakes with medical relevance can induce acute renal failure. In 
India, the incidence of AKI following Russels viper bite, the common  snake bite is 13–30%10. 
Mortality due to acute kidney injury resulting from snake bite ranges from 5 –50% in primary 
to tertiary health set up10.  These make snake bite an ideal clinical scenario to study the utility 
of proposed early renal biomarkers.  
While  precise  figures  for  global  snake  bite  epidemiology  are  not  available,  best 
estimates suggest that there are more than 2.5 million venomous snake bites annually, with 
greater than 125,000 deaths34. In India, a large proportion of snake bites occur when people are 
working barefoot in the fields, or while walking at night or early morning through fields or 
along roads. In temperate countries, most snake bites occur in summer among holiday makers 
in the coastal regions. 
. With some of the most dangerous species, such as the carpet viper, now invading cities 
and towns, urban dwellers are at increasing risk of fatal bites. There are more than 3000 species 
of snakes in the world but only about 350 are venomous10. 
Acute kidney injury (AKI) is unusual except with bites by Russells viper, E. Carinatus 
and members of the genera Crotalus and Bothrops. The most prevalent areas for these snakes 
are Asia and South America. Upto 90% of the approximately 1000 deadly snake bites occurring 
per annum in India and Burma are attributed to Russells viper which is also the fifth most 
common. cause of death  In Thailand, 70% of ARF cases have been ascribed to Russells viper 
envenomation. In India, ARF is mostly associated with Russells viper and E. carinatus bites. 
The snakes  of  the  genus  Bothrops  are  the leading cause of  venomous snake bite  in South 
America10.
The exact pathogenesis of ARF following snake bite in not well established. This is due 
to the lack of a reproducible animal model. However, a number of factors may contribute viz, 
bleeding, hypotension, circulatory collapse, intravascular hemolysis, disseminated intravascular 
coagulation, microangiopathic hemolytic anemia and also direct nephrotoxcity of the venom. 
Each of these factors is elucidated for better understanding of the pathogenesis and implication 
in AKI
Hypotension 
Bleeding either into tissues or externally and loss of plasma into the bitten extremity can 
produce hypotension and circulatory collapse. This is caused by venom metalloproteinases that 
degrade basement membrane proteins surrounding the vessel wall, leading to loss of integrity. 
Hemorrhagic  toxins  have  been  isolated  from  venom  of  many  snakes  of  Viperidae  and 
Crotalidae families. Additionally, vasodilatation and increased capillary permeability, both as a 
result of direct and indirect effects of venom, can aggravate the circulatory disturbances of 
shock. Irrespective of the cause, hypotension and circulatory collapse set in motion a chain of 
hemodynamic disturbances, which are known to culminate in ischemic ARF.
Intravascular hemolysis 
Major factor thought to have pathogenetic significance in snake-bite-induced ARF is 
intravascular  hemolysis.  Hemolysis  results  from the  action  of  phospholipase  A2  which  is 
present in almost all snake venoms and a basic protein called direct lytic factor, found only in 
elapid venoms. Phospholipase A2 causes hemolysis by direct hydrolysis of red cell membrane 
phospholipids  or  indirectly  via  the  production  of  the  strongly  hemolytic  lysolecithin  from 
plasma  lecithin.  Evidence  of  intravascular  hemolysis  in  the  form  of  anemia,  jaundice, 
reticulocytosis,  raised  plasma  free  hemoglobin,  abnormal  peripheral  blood  smear,  and 
hemoglobinuria is present in about 50% of patients following bites by the Russells viper and E. 
carinatus. In an experimental model using male Wistar rats, severe hemolysis was shown by 
increased plasma LDH levels, free hemoglobin and late presence of hemolysed red blood cell 
casts in renal tubules after infusion of venom.
Some have even suggested that renal failure following snake bite should be considered 
an example  of  the  hemolytic  uremic syndrome.  However,  while  intravascular  hemolysis  is 
frequently  observed,  microangiopathic  hemolysis  as  seen in  hemolytic  uremic syndrome is 
encountered only rarely. More over, more than 70-80% of patients with snake bite induced 
renal failure have only acute tubular necrosis and do not exhibit the glomerular and arteriolar 
changes characteristically associated with the hemolytic uremic syndrome.
Disseminated intravascular coagulation
The  human  haemostatic  system  is  regulated  via  a  number  of  critical  interactions 
involving  blood  proteins,  platelets,  endothelial  cells,  and  sub-endothelial  structures.  Snake 
venom proteins and peptides are known to activate or inactivate many of these interactions. 
Snake venoms, particularly those from the viper and pit viper families, contain many proteins 
that interact with members of the coagulation cascade and the fibrinolytic pathway.  Russells 
viper venom (RW) contains a factor V-activating serine proteinase, which has been separated 
from a factor X-activating protein, also present in this venom. The enzyme (RW-V) is a single 
chain glycoprotein with a molecular weight of 26,100 possessing one glycosylation site near 
the carboxyterminus. RW-V cleaves a single peptide bond to convert factor V to factor V a (the 
activated clotting protein).  Russells  viper  venom also contains a potent activator  of  human 
coagulation factor X; this enzyme has been well characterized and is designated as RW-X. 
Factor  X  activators  have  also  been  isolated  from Bothrops  atrox  and  several  other  snake 
species. Russells viper venom also activates factor IX by cleavage of a single peptide bond 
resulting in the formation of factor IX a.
There are several different types of prothrombin activators in snake venom. The activity 
of members of group I is not influenced by components of the prothrombin activator complex 
(factor  V a,  CaCI2 and phospholipid).   Ecarin,  from E.  carinatus venom, is  the most well 
studied member of this group. Group II activators resemble factor X a and can cleave both 
peptide bonds in prothrombin, leading to active 2-chain thrombin. Their activity is strongly 
stimulated by phospholipids and factor V a in the presence of Ca 2.  By contrast, activators in 
group II require only phospholipid and Calcium for the activation of prothrombin. They do not 
require factor Va, but appear to possess a co-factor that is tightly bound to the catalytic subunit 
that plays a similar role to factor Va in prothrombin activation. This class of activator is also 
found in Australian elapids and is represented by the high molecular weight activator from 
Taipan venom.
Although thrombin has many activities, the ability of some snake venom enzymes to 
clot fibrinogen has resulted in these enzymes being called “thrombin like”. [These are widely 
distributed primarily in the venom of snakes from true vipers (Bitis gabonica, Cerastes vipera) 
and pit  vipers (Agkistrodon contortrix, Crotalus adamanteus, Bothrops atrox). Snake venom 
fibrinogen clotting enzymes have been classified into several  groups based on the rates  of 
release of fibrinopeptides A and B from fibrinogen.
One mechanism of the anticoagulant action of snake venom proteins is attributed to the 
activation of protein C. Activated protein C degrades factors V a and VIIIa and therefore, has 
anticoagulant  activity.  Major  mechanism  of  anticoagulation  involves  inhibition  of  blood 
coagulation  factors  IX  and  X  by  a  venom  protein  that  binds  to  either  or  both.  Finally, 
anticoagulation  is  also  achieved  through  the  action  of  snake  venom  phospholipases  that 
degrade phospholipids involved in the formation of complexes critical to the activation of the 
coagulation pathway.  
Direct-acting fibrinolytic enzymes have also been isolated from the venom of a number 
of north and south American snakes, including rattlesnakes and copperheads, and from elapids, 
including  cobras  and  European  vipers.  The  venom  fibrinolytic  enzymes  that  have  been 
characterized in detail  are zinc metalloproteinases. Snake venoms also contain a number of 
platelet active components, including those that cause platelet aggregation and those that inhibit 
platelet aggregation. The final coagulation disturbance depends upon the balance among the 
activity  of  procoagulant,  anticoagulant,  fibrinolytic  and  fibrinogenolytic  components  of 
injected venom. Disseminated intravascular coagulation (DIC) is a consistent feature in patients 
bitten by Russells viper, E. carinatus, booms and pit vipers. The occurrence of DIC as a major 
hemostatic abnormality is well documented experimentally. Infusion of Russells viper or E. 
carinatus venom into rhesus monkeys resulted in abnormal coagulation parameters suggestive 
of DIC within two hours of injection of a lethal dose of the venom, but these changes first 
occurred from a few hours to three weeks after sub-lethal envenomation. 
The  presence  of  fibrin  thrombi  in  the  renal  microvasculature  and in  the  glomerular 
capillaries, and the findings of microangiopathic hemolytic anemia and thrombocytopenia in 
patients with cortical necrosis strongly suggest that DIC plays a major pathogenetic role in 
snake-bite  induced cortical  necrosis.   Snake venom initiates  a  chain reaction involving the 
coagulation, fibrinolytic,  kinin and complement systems. Venom-induced alterations lead to 
vascular coagulation and to deposition of fibrin thrombi in blood vessels. These changes occur 
in patients as well as in experimental models. Intraglomerular fibrin deposition of lesser degree 
has been suspected as causing acute tubular necrosis via a temporary hemodynamic alteration.
The role of the above factors in causing ARF was shown in an experimental model by 
Burdmann et al. They intravenously injected male Wistar rats with 0.4 mg/kg of russels viper 
venom and produced functional and morphological changes similar to those observed in human 
snake-bite  induced  ARF.  There  was  an  acute  and  significant  decrease  in  the  glomerular 
filtration  rate,  urine  output,  renal  plasma  flow  and  serum  fibrinogen  levels.  There  was 
intravascular  hemolysis,  as  shown  by  a  significant  decrease  in  hematocrit,  an  increase  in 
plasma  lactate  dehydrogenase  levels  and  free  hemoglobin.  Light  and  electron  microscopy 
showed  massive  fibrin  deposition  in  glomerular  capillaries  apart  from proximal  and distal 
tubular necrosis and red blood cell casts in renal tubules. In this model, ischemia related to 
glomerular  coagulation  and  intravascular  hemolysis  were  the  most  important  pathogenetic 
factors  causing  a  decrease  in  the  glomerular  filtration  rate,  although  direct  venom 
nephrotoxicity could not be excluded.
Direct nephrotoxicity
The earlier experimental studies performed on rabbits with russels venom did provide 
important clues to the evolution of glomerular lesions occasionally seen in human snake bite 
victims, but these do not seem to be relevant to patients developing renal failure, as most of 
them show histological changes of acute  tubular or cortical necrosis. Urinary beta-N acetyl 
showed considerable change in patients  bitten by Russells  viper,  without DIC, indicating a 
direct toxic effect of venom on the kidney. 
In a study, the administration of a lethal dose of Russells viper or E. carinatus venom to 
rhesus monkeys, resulted in hemorrhages in the kidneys and other organs in all animals, and 
mild acute tubular necrosis in 20% of animals, within 24 hrs of envenomation. After a sublethal 
venom dose, however, more than 50% of animals developed acute tubular necrosis, and fibrin 
thrombi  were  demonstrable  in  50-75%  of  glomeruli.  The  histological  findings  and  the 
coagulation  abnormalities  observed  in  these  animals  were  similar  to  those  seen  in  human 
victims  of  snake  bite.  The  strongest  evidence  supporting  direct  nephrotoxcity  is  a  dose-
dependent decrease in inulin clearance and an increase in fractional excretion of sodium in the 
isolated perfused rat kidney, following russels viper envenomation. 
On morphological analysis, the most prominent structural lesions were observed in the 
renal cortex. Extensive damage and loss of glomerular epithelial cells and endothelium was 
detected  with  only  the  basement  membrane  remaining.  Ballooning  and  even  rupture  of 
glomerular capillaries could be seen. Major prominent feature of russels viper venom action on 
renal  cortex,  and likewise on all  other renal  zones,  concerned vessels  with muscular  walls 
(arteries, veins, arterioles, venules).The venom led to complete lysis of vascular smooth muscle 
cells  leaving  behind  only  the  basement  membrane.  Varying  degrees  of  epithelial  injury 
occurred in  all  tubular  segments  In  addition myoglobinuria,  sepsis,  and hypersensitivity  to 
venomous  or  anti-venomous  protein  may  also  contribute  towards  renal  failure.  Crescentic 
nephritis  in  patients  bitten  by  puff  adder  snake  has  been  attributed  to  hypersensitivity  to 
antisnake venom. Myoglobinuria generally occurs following sea snake envenomation, which 
results in necrosis of striated muscles and muscular paralysis. 
In patients with ARF, oliguria often develops rapidly within the first 48 hrs, but may be 
delayed till 3-4 days after the bite. Some patients become anuric, whereas occasional patients 
remain non-oliguric. Urine may show gross or microscopic hematuria. Some patients complain 
of pain in the renal angle preceding oliguria, which may be a useful clue to impending renal 
failure. Jaundice and hemoglobinuria resulting from intravascular hemolysis are not infrequent 
following Russells viper or E. carinatus bites and have been reported from India and Sri Lanka. 
Daily urine protein concentration may exceed one gram, and erythrocyte casts may also be 
seen. Hypertension has been infrequently recorded after both viper and sea snake bites. The 
mortality of patients with renal failure varies with the nature of the renal lesion. Although only 
16% of those with acute tubular necrosis, in whom uremia was controlled with dialysis, died, as 
many as 80% of those with cortical necrosis had a fatal outcome 10. 
Renal Histology in snake bites
Renal histology shows predominantly either acute tubular or cortical necrosis. A number 
of glomerular changes have been described but their significance is not known.
1.Acute Tubular Necrosis
Acute tubular necrosis is the predominant lesion seen in 70-80% of patients with ARF. 
On light microscopy, the tubules appear dilated and lined by flattened epithelium. Severe cases 
exhibit cell necrosis and desquamation of necrotic cells from the basement membrane. Hyaline, 
granular or, pigment casts are seen in tubular lumina. Varying degrees of interstitial edema, 
hemorrhage, and inflammatory cell infiltration are present. Later biopsies reveal regenerating 
tubular  epithelium.  Intrarenal  blood  vessels  are  usually  unaffected.  On  ultrastructural 
examination, proximal tubules show dense intra-cytoplasmic bodies representing degenerating 
organelles  or  protein resorption droplets.  Small  areas  of  basement  membrane are  denuded. 
Distal tubular cells have a dilated endoplasmic reticulum and many degenerating organelles. 
Apoptosis is a prominent feature in the distal tubules, indicating a high cell turnover. In the 
interstitium, fibroblasts appear active, with increased numbers of organelles and cytoplasmic 
processes. Mast cells and eosinophils show both granulated and partially degranulated forms.
Although  the  blood  vessels  appear  normal  under  light  microscopy,  ultrastructural 
abnormalities  are  notable  in  both  large  and  small  caliber  vessels.  Medullary  vessels  are 
severely affected, with markedly swollen, focally  necrotic,  endothelial  cells obliterating the 
lumen. Smooth-muscle cells show cytoplasmic vacuoles, which are empty or are filled with 
granular material. The severe vascular lesions, distal tubular apoptosis, and presence of mast 
cells,  eosinophils,  and active  fibroblasts  in  the  interstitium are  features  that  have not  been 
observed in acute tubular necrosis from other causes. 
2.Acute Cortical Necrosis
Bilateral diffuse or patchy cortical necrosis  has been observed following bites  by E. 
carinatus. Cortical necrosis appears to be more common among Indian patients than among 
patients in other south-asian regions, for unknown reasons.  The presence of fibrin thrombi in 
the arterioles is a prominent feature in these patients. A narrow subcapsular rim of cortex often 
escapes necrosis. The area underlying this, however, shows necrosis of glomerular as well as 
tubular elements. The necrotic zone is often bordered by an area of hyperemia and leukocytic 
infiltration.  Calcification of necrotic  areas  may occur  at  a  later stage.  Varying numbers  of 
glomeruli  are  spared  in  patients  with  patchy  cortical  necrosis.  With  healing,  fibroblastic 
proliferation and organization of thrombi are  seen.
3.Glomerular Lesions
Whether or not specific glomerular lesions really occur is still controversial patients. 
diffuse glomerular hypercellularity (ascribed to marked mesangial proliferation), ballooning of 
capillaries,  endothelial  swelling,  mesangiolysis  and  splitting  of  the  glomerular  basement 
membrane; however,  the significance of these is  difficult to ascertain.  Immunofluorescence 
microscopy  showed  1gM,  C3,  and  fibrin  deposits.   In  occasional  instances,  a  diffuse  and 
intense mononuclear cell infiltrate has been noted in the interstitium, suggesting the occurrence 
of an acute interstitial nephritis.
Various  factors  contribute  to  the  pathogenesis  of  acute  renal  failure  in  snake  bite, 
namely  bleeding,  hypotension,  circulatory  failure,  intravascular  hemolysis,  disseminated 
intravascular  coagulation,  microangiopathic  hemolytic  anemia  and  more  importantly  direct 
nephrotoxicity of the venom.  
Renal histology shows that the predominant lesion is acute tubular neurons (ATN) in 70 
– 80% with mortality rate of 16% and those with cortical necrosis, the mortality rate was found 
to be as high as 60%.
  Mortality due to acute kidney injury resulting from snake bite ranges from 5 –50% in 
primary to tertiary health set up10. Major reason for this alarming number is late recognition of 
developing AKI and delayed referral to tertiary set up with renal replacement facilities
Animal models and human studies strongly suggest that early treatment is the key to 
preventing AKI and halting the progression of disease. Existing biomarkers are found to be 
inadequate for earlier detection and timely prevention or intervention (fluid replacement as 
hypotension plays a major role in AKI due to snake bite or  renal replacement therapy).
Urea and Creatinine : Need for another marker?
The loss of kidney function in acute renal failure is most easily detected by measurement 
of the serum creatinine, which is used to estimate the glomerular filtration rate (GFR).
            A low serum creatinine concentration may be misleading in patients with reduced 
muscle mass.  In addition, serum creatinine is somewhat insensitive index of renal function, 
especially in early and late stages of renal disorder.
.  
Graph4:  Relationship between serum creatinine and actual values of eGFR in patients 
with renal failure.  Normal value of serum creatinine is indicated by dashed line. 
Above graph shows the relative insensitivity of creatinine when GFR falls
140ml/min/1.73m2  to 40ml/min/1.73m2  .This depicts creatinine is slow to rise even when there 
is considerable fall in GFR .
Two mechanisms account for relative insensitivity of serum creatinine and urea as an 
indication of acute renal injury.  As part of adaptation of the kidney to renal injury, uninjured 
nephrons undergo hypertrophy and hyper filtration.  Thus, total GFR and serum creatinine and 
urea remain relatively normal despite a decrease in functioning nephrons2,3,6,9,12.
Another  potential  problem  is  that  tubular  secretion  of  creatinine,  which  normally 
contributes  little  to  overall  creatinine  clearance,  increases  progressively  as  renal  disease 
worsens.  
Thus,  both  serum  creatinine  concentration  and  the  creatinine  clearance  becomes 
increasingly unreliable as estimates of GFR in patients with early renal disease.
Finally, certain circumstances are associated with spurious elevation of serum creatinine 
independent of changes in GFR.  Rhabdomyolysis / ingestion of loaded meat, certain drugs, 
ketoacidosis, and acrobatics can be detected to have raised creatinine due to protein catabolism 
leading to false elevation.        
Serum creatinine has failed as a reliable marker of renal dysfunction for various reasons 
– many non renal factors cause changes in creatinine levels, its increase is not directly related 
due to  tubular  injury  but an effect  of reduced GFR in AKI.   There is  also a  delay in  the 
detectable  increase  in  serum  creatinine  that  is  sometimes  marked  by  intravenous  fluid 
administration and many a time this becomes too late which is reflected in the morbidity and 
mortality rate of AKI using urea and creatinine in detecting AKI.
So, better biomarkers are needed to spot AKI early and prevent progression.  
EMERGING  BIOMARKERS — Although  the  serum  creatinine  is  widely  used  in 
diagnosing  the  presence  of  acute  renal  failure,  it  is  a  poor  biomarker  for  this  process 
principally due to its inability to help diagnose early acute renal failure and complete inability 
to help differentiate among its various causes [21] . As an example, the rise in serum creatinine is 
slow following the onset of acute renal failure. By the time a change is observed in the serum 
creatinine, a critical therapeutic window may have been missed, particularly among those with 
ATN.      
    Thus, different urinary and serum proteins have been intensively investigated as 
possible biomarkers for the early diagnosis of ATN. There are promising candidate biomarkers 
with the ability to detect an early and graded increase in tubular epithelial cell injury and to 
distinguish prerenal disease from acute tubular necrosis 21,22. 
     Neutrophil Gelatinase Associated Lipocalcin(NGAL), cystatin-C, Urinary IL – 
18(UIL18), Kidney Injury Molecule (KIM-I) are some of them1,2,8.
               Urinary and plasma levels of NGAL were evaluated in a pilot study of 71 children 
undergoing cardiopulmonary bypass to identify very early markers for ATN  [33]    .  Urinary 
NGAL levels obtained at two hours following procedure correlated with severity and duration 
of AKI, length of stay, requirement for dialysis, and death. Urinary kidney injury molecule-1 
— Kidney injury  molecule-1  (KIM-1) is  a  type 1 transmembrane  glycoprotein  that  shows 
marked upregulation in the proximal tubule with AKI [39] ;the ectodomain is shed and can be 
measured in urine by immunoassay. Kim-1 has been tested in a number of small cohorts [19,40] .
                  Serum and Urinary IL-18 is also shown to be markedly raised in AKI in various 
cross sectional studies.  Previous studies have shown sensitivity and specificity of >90% in 
diagnosing AKI11,13.
        IL-18 is one of the numerous pro-inflammatory cytokines produced in the body. 
IL-18 belongs to IL-1, super family of cytokines.  The activities of IL-18 appear to species – 
specific. An important function of IL-18 is the regulation of functionally distinct subsets of T-
helper cells required for cell mediated immune responses.  IL-18 functions as a growth and 
differentiation of TH1 cells9,13,24.
It  is  produced  during  the  acute  immune  response  by  macrophages  and  immature 
dendritic cells.  It is also produced by epithelial lining of lungs and distal and proximal tubules 
of kidney24.  This fact is responsible for acute rise of urinary IL18 seen in tubular necrosis.
Urinary  interleukin  18  has  been  found  to  be  a  useful  tool  in  various  experimental 
studies.  Serum  and  urinary  levels  are  raised  in  many  clinical  settings  like  pulmonary 
sarcoidosis,  idiopathic  pulmonary  fibrosis,  multiple  sclerosis,  closed  head  injury,  crohns 
disease, diabetic nephropathy, coronary artery disease22.  Its elevation is also correlated with 
increased  carotid  intimal  medial  thickness24.  Many  of  these  depict  IL18  to  be  a  surrogate 
marker of infection and inflammation.24
Urinary Interleukin-18 may be involved in sleep disorders in end-stage renal disease 
patients  Higher  plasma interleukin-18 levels  are  associated with poorer  quality  of  sleep in 
peritonealdialysis  patients24.  Whether  a  cause-and-effect  relationship  exists  between 
interleukin-18 and quality of sleep are under further investigation27 Increased serum and urine 
IL-18 levels were observed during relapse of idiopathic nephrotic syndrome.  These findings 
indicate the association between the active phase of idiopathic nephrotic syndrome and the 
levels of IL-18 and can suggest the role of this cytokine in this syndrome. Serum levels of IL-l8 
might be a predictor of progression of diabetic nephropathy as well as cardiovascular diseases.
Urinary  IL-18 levels  start  increasing within 6 –12 hours  of kidney assault,  much in 
advance  to  in  blood  urea  nitrogen  (BUN)  and  creatinine  concentration1,5,24.   In  another 
prospective study with intensive care patients, the urine IL-18>100 pg/ml was predictive of 
AKI developing within 24 hours13,24.
In a country like ours, where mortality from acute kidney injury has been high, early 
recognition and prompt intervention will  be required to save lives.  Last, intensive medical 
resources should be made available in all centres to help patients developing AKI.                    
                                   MATERIALS AND METHODS
SETTING
In-patients
           Toxicology ward
           Institute of internal medicine 
Madras Medical College and Government General Hospital
Chennai-600 003
ETHICAL COMMITTEE APPROVAL
Obtained
STUDY DESIGN
Single centre, description, cross sectional, non-interventional study
PERIOD OF STUDY
March 2008 – March 2009
SAMPLE SIZE
80 patients
SELECTION OF STUDY PATIENTS
INCLUSION CRITERIA
Patients admitted in Toxicology with snake bite.
EXCLUSION CRITERIA
1. Patients with existing renal parenchymal disease.
2. Other conditions predisposing to AKI such as diabetes mellitus, hypertension, sepsis, 
shock and cardiovascular disease.
3. Conditions  associated  with  raised  IL-18  levels-  cellulites,  crohn’s  disease,  acute 
pancreatitis,  obesity,  multiple  sclerosis,  pulmonary  sarcoidosis,  raised  ICT, 
cerebrovascular events and presence of any infection or inflammation.
4. Patients  with serum creatinine  > 1.2 mgs/dl  and those  who received nephrotoxic 
agents
        
 
METHODOLOGY
The study was conducted in the toxicology wards in the Institute of Internal Medicine, 
Madras Medical College and Government General Hospital, Chennai.
Patients admitted with snake bite were asked to collect 5 ml of midstream urine at 12, 
24,  and  48  hours  after  bite.   Their  daily  urine  output  was  also  charted.   Urine  bags  of 
catheterized  patients  were  measured  and  emptied  one  hour  prior  to  collection  to  make 
collection of sample uniform and without much alteration due to concentration of urine. Of the 
original 104 patients, 80 were enrolled as some were dropped as they could not be relied on the 
exact time of bite and others could not collect specimen at stipulated time.  
           Samples were collected in a sterile container and freezed until they were thawed and 
centrifuged at 4000 rpm at 4°C for 10 minutes.  The supernatant was aliquotted equally into 
cryovials  and  freezed  under  -20°C  until  UIL-18  was  measured  using  Human  IL-18  (ray 
bio,Medical  and Biologic laboratory,  Nagoya, Japan)  kit.   This  detects  the mature form of 
IL-18.  The cross reactivity of pro-IL18 is extremely low.  The co-efficient of inter and intra 
assay for the kit ranges from   5 – 10%.
Assay Procedure   
1. Bring samples and reagents to room temperature.
2. Prepare all reagents, samples and standard as instructed.
3. Add 100 micro liter standard or sample to each wall.  Incubate 2.5 hours at room 
temperature or over night at 4°C.
4. Add 100 micro liter prepared biotin antibody to each wall.  Incubate 1 hour at room 
temperature.
5. Add 100 micro liter of prepared streptavidin solution.  Incubate 45 minutes at room 
temperature.
6. Add 100 micro liter one step substrate reagent to each wall.  Incubate 30 minutes at 
room temperature.
7. Add 50 micro liter stop solution to each wall.
8. Read at 450 nm immediately.
The standard concentration was diluted to 500, 250, 125, 100, 50.
CALCULATION OF RESULTS
Samples are read using ELISA reader in biochemistry department.  Calculate the mean 
absorbance  for  each  set  of  standards,  controls  and  samples  and  subtract  the  average  zero 
standard optical density.  Plot the standard curve by using sigma plot software, with standard 
concentration on the X-axis and absorbance on the Y-axis.   Draw the best fit  straight line 
through the standard points.
STANDARD CURVE FROM HUMAN IL-18 ASSAY KIT.
TEST CURVE FROM OUR DILUTED STANDARDS
All samples are read at 450 nm and optical density obtained is converted into pg/ml 
through a computer fed program.
The data thus obtained are charted with help of Microsoft XP and statistical analysis 
using statistical package for social sciences (SPSS 12).
RESULTS
Eighty patients  who presented with snake bite  at  the  Toxicology Department of  the 
Government General Hospital,  Chennai,  India,  between March 2008 and March 2009 were 
enrolled  in  the  study,  based  on  the  inclusion  and  exclusion  criteria  described  earlier  (see 
Patients  and  Methods).  In  each  of  the  patients,  the  serum creatinine  (mg/dL),  blood  urea 
(mg/dL) and urinary      IL-18 (pg/ml) concentrations were evaluated at 12 hours, 24 hours and 
48 hours after admission. 
To facilitate analysis of the data, the 80 patients were divided into            4 groups:
a) Group I (39 patients):  
Patients without acute kidney injury (AKI) and with urinary                  IL-18 levels 
below100 pg/ml.
b) Group II (4 patients):  
Patients without AKI and with urinary IL- 18 levels at or above                                 100 
pg/ml.
c) Group III(16 patients):  
Patients with AKI and with urinary IL- 18 levels below 100 pg/ml.
d) Group IV(21 patients):  
Patients with AKI and with urinary IL- 18 levels at or above100 pg/ml.
DIFFERENT GROUPS
TABLE 1
EVALUATION OF SERUM CREATININE LEVELS
Hours 
after 
admission
Group 
I(n=39)
Group II (n=4) Group III (n=16) Group IV (n=21)
12 hrs 0.74 ± 0.16 0.70 ± 0.26 0.83 ± 0.27 0.76  ± 0.18
24 hrs 0.74 ± 0 .18 0.90 ±0.26 1.14 ± 0.31 a* d† 0.82 ± 0.23 c*
48 hrs 0.78 ± 0.19 0.90 ± 0.26 2.09 ± 0.36 a* b* d* e* 2.35 ± 0.63 a* b* c‡  d* e*
At 12 hours, there were no significant differences between the mean serum creatinine 
levels in patients in groups I, II, III and IV, with the values being within the normally accepted 
range.
At 24 hours,  the mean serum creatinine level  in group III  patients was significantly 
higher (P<0.001) than that in group I patients and significantly higher (P<0.001) than that in 
group IV patients, but still within the normally accepted range.
At 48 hours, the mean serum creatinine levels in patients in groups III and IV were 
significantly  higher  (P<  0.001  and  P<0.001,  respectively)  than  that  in  group  I  patients; 
similarly, the mean serum creatinine levels in patients in groups III and IV were significantly 
higher (P< 0.001 and P<0.001, respectively) than that in group II patients.  In addition, the 
mean serum creatinine level in group IV patients was significantly higher (P< 0.05) than that in 
group III patients. The mean serum creatinine levels in group III and group IV patients at 48 
hours were higher than the upper limit of the normally accepted range. 
In  group  I  patients,  there  were  no  significant  differences  between  the  mean  serum 
creatinine levels at 12 hours, 24 hours and 48 hours, and the values were within normal limits. 
Similarly, in group II patients, there were no significant differences between the mean serum 
creatinine levels measured at 12 hours,  24 hours and 48 hours, and the values were within 
normal limits. 
In  group III  patients,  the  mean serum creatinine  level  at  24 hours  was  significantly 
higher (P<0.01) than that at 12 hours, but was still within normal limits. However, at 48 hours, 
the mean serum creatinine level was significantly higher than that at 12 hours (P<0.001) and 
that at 24 hours (P<0.001) and was higher than the upper limit of the normally accepted range. 
In group IV patients, the mean serum creatinine level at 24 hours was essentially similar 
to that at 12 hours, and within normal limits. However, at 48 hours, the mean serum creatinine 
level was significantly higher than that at 12 hours (P<0.001) and that at 24 hours (P<0.001) 
and was higher than the upper limit of the normally accepted range. 
Values are expressed as mean ± SD. 
Statistical analyses (*, †and ‡ represent P < 0.001, P < 0.01 and P < 0.05, respectively). 
a Group I vs. groups II, III, IV values
b Group II vs. groups III, IV values
c Group III vs. group IV values
d 12 hours vs. 24, 48 hours
e  24 hours vs. 48 hours
a) Group I  :  Patients  without  acute kidney injury (AKI) and with urinary IL- 18 levels 
below 100 pg/ml;
b) Group II  : patients without AKI and with urinary IL- 18 levels at or above 100 pg/ml;
c) Group III  : patients with AKI and with urinary IL- 18 levels below 100 pg/ml;
d) Group IV  : patients with AKI and with urinary IL- 18 levels at or above 100 pg/ml
2. Evaluation of blood urea levels (Table 2)
    Table 2.  
Mean blood urea levels (mg/dL) in study patients
Hours after 
admission Group I (n=39) Group II (n=4) Group III (n=16) Group IV (n=21)
12 hrs 29.44 ± 6.50 29.50 ± 7.72 35.25 ± 8.73 a† 28.33 ± 6.19 c†
24 hrs 31.57 ± 5.81 30.50 ± 5.74 41.31 ± 5.78 a‡  36.77 ± 23.45 d‡  
48 hrs 33.03 ± 5.88 34.50 ± 4.12 58.06 ± 7.35 a* b* d* e* 67.95 ± 21.19 a* b* c‡ d* e*
At 12 hours and 24 hours, there were no significant differences between the mean blood 
urea levels in patients in groups I, II and IV, with the values being within the normally accepted 
range. In group III patients, the mean blood urea levels were significantly higher than those in 
group I patients at 12 hours (P<0.01) and 24 hours (P<0.05) and was also significantly higher 
(P<0.01)  than  the  level  in  group  IV patients  at  12  hours,  but  the  values  were  within  the 
normally accepted range.   
At  48  hours,  the  mean  blood  urea  levels  in  patients  in  groups  III  and  IV  were 
significantly  higher  (P<  0.001  and  P<0.001,  respectively)  than  that  in  group  I  patients; 
similarly, the mean blood urea levels in patients in groups III and IV were significantly higher 
(P< 0.001 and P<0.001, respectively) than that in group II patients. In addition, the mean blood 
urea level in group IV patients was significantly higher (P< 0.05) than that in group III patients. 
The mean blood urea levels in group III and group IV patients at 48 hours were higher than the 
upper limit of the normally accepted range. 
In group I patients, there were no significant differences between the mean blood urea 
levels at 12 hours, 24 hours and 48 hours, and the values were within normal limits. Similarly, 
in group II patients, there were no significant differences between the mean blood urea levels 
measured at 12 hours, 24 hours and 48 hours, and the values were within normal limits.  
In  group  III  patients,  the  mean  blood  urea  level  at  24  hours  was  not  significantly 
different from that at 12 hours, and the levels were within normal limits.  However, at 48 hours, 
the mean blood urea level was significantly higher than that at 12 hours (P<0.001) and that at 
24 hours (P<0.001) and was higher than the upper limit of the normally accepted range. 
In group IV patients, the mean blood urea level at 24 hours was significantly higher (P < 
0.05) than that at 12 hours, but was within normal limits. However, at 48 hours, the mean blood 
urea  level  was  significantly  higher  than  that  at  12  hours  (P<0.001)  and  that  at  24  hours 
(P<0.001) and was higher than the upper limit of the normally accepted range. 
Values are expressed as mean ± SD. 
Statistical analyses (*, †and ‡ represent P < 0.001, P < 0.01 and P < 0.05, respectively) 
a Group I vs. groups II, III, IV values
b Group II vs. groups III, IV values
c Group III vs. group IV values
d 12 hours vs. 24, 48 hours
e  24 hours vs. 48 hours
a) Group I  : Patients without acute kidney injury (AKI) and with urinary     IL- 18 levels 
below 100 pg/ml;
b) Group II  : patients without AKI and with urinary IL- 18 levels at or above 100 pg/ml;
c) Group III  : patients with AKI and with urinary IL- 18 levels below         100 pg/ml; 
d) Group IV  : patients with AKI and with urinary IL- 18 levels at or above  100 pg/ml.
3. Evaluation of urinary IL-18 levels (Table 3)
Table 3
Mean urinary concentrations of IL-18 in study patients
Hours
After 
admission
Mean levels 
(pg/ml) in 
group I
 (n=39)
Mean levels 
(pg/ml) in group II
(n=4)
Mean levels 
(pg/ml) in  group 
III
 (n=16)
Mean levels  (pg/ml) in 
group IV
 (n=21)
12 hrs 18.47 ± 10.43 21.05 ± 17.12 27.34 ± 22.83 21.00  ± 16.10
24 hrs 19.57 ± 9.95 119.35 ± 17.94  a* d* 49.54 ± 21.76 a* b* d* 114.70 ± 12.33 a* c* d*
48 hrs 23.65 ± 11.93 142.70 ± 53.15 a* d* e‡ 82.22 ± 8.96 a* b* d* e* 147.55 ± 28.33 a* c* d* e*
At  12  hours,  there  were  no  significant  differences  between  the  mean  urinary 
concentrations of IL-18 in patients in groups I, II, III and IV, and the levels ranged from 18.47 
+ 10.43 to 27.34 + 22.83 pg/ml (Table 3). 
At 24 hours, the mean urinary concentrations of IL-18 in patients in groups II, III and IV 
were  all  significantly  higher  (P<0.001,  P<0.001  and  P<0.001,  respectively)  than  the  mean 
concentration in group I patients. Moreover, the mean urinary concentration of IL-18 in group 
III  patients,  although  significantly  higher  (P<0.001)  than  that  in  group  I  patients,  was 
significantly  lower  than  that  in  group II  patients  (P<0.001)  and  that  in  group  IV patients 
(P<0.001). The mean concentrations ranged from 49.54  + 21.76 to 119.35  + 17.94 pg/ml in 
patients in groups II, III and IV.  
At 48 hours, the mean urinary concentrations of IL-18 in patients in groups II, III and IV 
were  all  significantly  higher  (P<0.001,  P<0.001  and  P<0.001,  respectively)  than  the  mean 
concentration in group I patients. Moreover, the mean urinary concentration of IL-18 in group 
III  patients,  although  significantly  higher  (P<0.001)  than  that  in  group  I  patients,  was 
significantly  lower  than  that  in  group II  patients  (P<0.001)  and  that  in  group  IV patients 
(P<0.001).  The mean concentrations ranged from 82.22  + 8.96 to 147.55  + 28.33 pg/ml in 
patients in groups II, III and IV.  
In group I patients, the mean urinary concentrations of IL-18 at 24 hours and at 48 hours 
were not significantly different from that at 12 hours. In group II patients, the mean urinary 
concentration of IL-18 at 24 hours was significantly higher (P<0.001) than that at 12 hours, 
while the mean IL-18 concentration at 48 hours was significantly higher than that at 12 hours 
(P<0.001) and that at 24 hours (P<0.05). In group III patients, the mean urinary concentration 
of IL-18 at 24 hours was significantly higher (P<0.001) than that at 12 hours, while the mean 
IL-18 concentration at 48 hours was significantly higher than that at 12 hours (P<0.001) and 
that at 24 hours (P<0.001). In group IV patients, the mean urinary concentration of IL-18 at 24 
hours  was  significantly  higher  (P<0.001)  than  that  at  12  hours,  while  the  mean  IL-18 
concentration at 48 hours was significantly higher than that at 12 hours (P<0.001) and that at 
24 hours (P<0.001). 
Values are expressed as mean ± SD. 
Statistical analyses (*, †and ‡ represent P < 0.001, P < 0.01 and P < 0.05, respectively) 
a Group I vs. groups II, III, IV values
b Group II vs. groups III, IV values
c Group III vs. group IV values
d 12 hours vs. 24, 48 hours
e  24 hours vs. 48 hours
a) Group I   (39 patients): patients without acute kidney injury (AKI) and with urinary IL- 
18 levels below 100 pg/ml;
b) Group II   (4 patients): patients without AKI and with urinary IL- 18 levels at or above 
100 pg/ml;
c) Group III  (16 patients):  patients  with AKI and with urinary IL- 18 levels  below 100 
pg/ml;
d) Group IV  (21 patients): patients with AKI and with urinary IL- 18 levels at or above 100 
pg/ml
4. Evaluation of a urinary IL-18 concentration of >100 pg/ml at 24 hours as a      diagnostic aid 
for acute kidney injury (table 4)
Table 4
Urinary IL-18 
level
AKI Present
AKI not 
Present
Total
≥100 pg/ml 21  4 25
<100 pg/ml 16 39 55
Total 37 43 80
According to Parikh et al,  a urinary IL-18 concentration of  >100 pg/ml at 24 hours can 
be used to predict the occurrence of  acute kidney injury. This aspect was examined in the 
present study by constructing a 2 X 2 table and then calculating important parameters. The 
following results were obtained: sensitivity of 56.76 % , specificity of 90.70 %,  predictive 
value of a positive test of 86 %,  predictive value of a negative test of  71 %,  false-positive rate 
of  5 %, false-negative rate of 20%. 
PARAMETERS 
a) Sensitivity (21/37 x 100) = 56.76 %
b) Specificity (39/43 x 100) = 90.70 %
c) Predictive value of positive test (21/25 x 100) = 86 %
d) Predictive value of negative test (39/55 x 100) = 71 %
e) False-positive rate (4/80 x 100) = 5 %
f) False-negative rate (6/80 x 100) = 20 %
5. Evaluation of a urinary IL-18 concentration of  > 40 pg/ml at 24 hours as a diagnostic aid for 
acute kidney injury 
Table 5
Urinary IL-18 
level
AKI Present
AKI not 
Present
Total
≥40 pg/ml 32   7 39
<40 pg/ml  5 36 41
TOTAL 37 43 80
In an attempt to improve the sensitivity of the screening procedure using urinary IL-18 
concentrations without marked loss of specificity, and to reduce the false-negative rate without 
a marked increase in the false-positive rate, another approach was taken.  The normal range of 
urinary IL-18 at 24 hours was calculated (based on the values obtained in group I patients at 24 
hours in the present study).
Mean concentration of urinary IL-18 at 24 hours in 39 normal (Group I) patients: 
= 19.57 + 9.95 pg/ml .
Normal range (95.45% accuracy)  = Mean value + 2 SD
                                                    = 19.57 + (2 x 9.95)
                                                     = 19.57 +   19.9
                                                   = 39.47 pg/ml
Accordingly, a concentration of  > 40 pg/ml at 24 hours was taken as a `break-point’ 
concentration to predict the occurrence of acute kidney injury. 
When this value was taken, the following results were obtained: 
a) Sensitivity = 86.48 %
b) Specificity = 83.72 %
c) Predictive value of positive test = 82.05  %
d) Predictive value of negative test = 87.8   %
e) False-positive rate = 8.75 %
f) False-negative rate = 6.25 %      
PARAMETERS 
a) Sensitivity (32/37 x 100) = 86.48 %
b) Specificity (36/43 x 100) = 83.72 %
c) Predictive value of positive test (32 / 39 x 100) = 82.05  %
d) Predictive value of negative test (36 / 41 x 100) = 87.8   %
e) False-positive rate (7/80 x 100) = 8.75 %
f) False-negative rate (5/80 x 100) = 6.25 %
Statistical analysis
The  values  are  expressed  as  mean  ±  standard  deviation  (SD).  Differences  between 
groups were assessed by one-way analysis of variance (ANOVA) using SPSS software package 
for Windows (Version 11.5; SPSS Inc., Chicago, IL, USA).  Post hoc testing was performed 
for intergroup comparisons using the least significance difference (LSD) test. Values of  P < 
0.001, 0.01 and 0.05 have been denoted by distinct symbols in the tables.
DISCUSSION
AKI is defined by acute changes in serum creatinine, which for many reasons mentioned 
before is a late and non-specific marker of AKI.  AKI is emerging as a public health problem 
since  epidemiologic  studies  reveal  that  mild  increase  in  serum  creatinine  of  hospitalized 
patients  are associated with increased mortality  and morbidity6.  Several  urinary biomarkers 
have been identified as potential candidates for AKI detection prior to serum creatinine rise.
Animal  studies  show  that  intra  renal  IL-18  production  is  involved  in  the 
pathophysiology of ischemic AKI independent of neutrophil8,29,32,35.  Human studies revealed 
that UIL-18 concentrations rise 24 – 48 hours prior to AKI in two meta-analytic study in ICU 
set up.  Reports were not promising in few studies conducted in Japan in predicting contrast 
induced nephropathy.
Parikh et al reported the results of a nested case control study analyzing the sequential 
urine samples from patients enrolled in ARDS trials.  They found that UIL18 levels >100 pg/ml 
were predictive of AKI developing within 2 days5,24,29.
Earlier in 2005, neutrophil gelatinase associated lipocalcin (NGAL) was identified as a 
highly sensitive and specific marker of AKI following cardiac surgery in pediatric patients.
The discriminatory capacity of biomarkers is based on data from trials that used different 
inclusion and exclusion criteria and different definitions of AKI, making comparison difficult.
The current study is the first to:
1. Systematically examine the relationship between UIL18 and AKI comparing with 
urea and creatinine in snake bite patients.
2. To examine the impact of UIL18 utility as AKI biomarker.
The range of urinary IL-18 in different studies ranges from 10 – 25 pg/ml and serum 
level of 15 – 70 pg/ml12,13.  According to Parikh et al in ARDS trial, elevation in urinary IL-18 
>100 pg/ml at 24 hours predicted AKI 2 days prior to the kidney (sensitivity 95%, specificity 
80%) injury manifesting as creatinine and BUN rise29,32,34.
In the present study, mean concentration of urinary IL-18 at  24 hours in 39 normal 
(group I) patients was found to be 19.57 ± 9.95 pg/ml.  So, the normal range in the population 
would be from 0 – 40 pg/ml (0.57 – 39.47 pg/ml by Mean ± 2 SD).
The  following  results  were  obtained  on  using  100  pg/ml  as  cut-off  to  predict  AKI 
developing within 24 hours – sensitivity of 56.76%, specificity of 90.7%.  The predictive value 
of a positive and negative test was around 86% and 76% respectively.
Accordingly, when 40 pg/ml, the upper limit of normal range was taken as “break-point” 
concentration  to  predict  the  occurrence  of  acute  kidney injury,  the  sensitivity  increased to 
86.48% with a mild drop of specificity from          90.7 to 83.7%.  The predictive value of 
positive and negative test remained at 82.05% and 87.5% respectively.
The most important goal for studying AKI biomarkers is AKI detection prior to serum 
creatinine rise.   On comparing the mean tables of urea, creatinine (Tables 1,  2 and 3) and 
UIL18, it is seen that UIL18 rises atleast 24 hours prior to rise in BUN and creatinine if 40 mg/
ml is taken as a reference point on contrary to 48 hrs according to Parikh et al.
Unfortunately our sample study was not large enough to categorize and differentiate 
patients with fluid respective elevation in serum creatinine (pre-renal) from renal injury as seen 
with acute tubular necrosis.
Snake bite above caused AKI by various mechanism mentioned previously. The most 
common among them was direct tubular injury. Some in group II did have a rise in UIL18, but 
did not progress to AKI as per creatinine levels.  This is due to minimal insult from toxin of 
snake  bite  which  got  aborted  early  and this  is  also  the  reason  for  positive  predictive  and 
negative predictive value to be perched at mid 80’s as UIL18 also picked up patients who 
develop kidney insult even when it did not show in creatinine levels later.
The observation adds to the emerging evidence that UIL-18 could serve as diagnostic 
index in AKI.  Even though some studies did suggest UIL-18 to be a prognostic marker, since 
outcome was not  followed in  our  study,  it  could  not  be  commented.   But  there  were  two 
patients  who died of  AKI was found to  have very high levels  UIL-18 (<150 pg/ml when 
compared to 40 pg/ml for AKI).  Whether this is just a coincidence or a causal factor needs 
further large scale study and statistical co-relation. 
Even though, the sensitivity and specificity are convincingly high        (>40 pg/ml) and 
the cost low for the test to be a screening tool, there are few points to be addressed before it can 
be considered for clinical decision making.  Use of UIL18 is further complicated by its role as 
mediator of inflammation and its association with mortality.   These lead to exclusion criteria to 
be many and their wide range of normal value in population.  Urinary biomarkers also have a 
inherent limitation of being influenced by urine volumes, so their concentrations should be 
normalized  to  excretion  of  other  solutions.  (e.g.  creatinine).   Large  prospective  studies  of 
patients in different settings will be required to ascertain the relationship of these markers to 
each other and to establish their capacity to predict outcomes.      
UIL18  levels  in  pre-renal  azotemia  should  be  studied  and  their  reference  point  of 
reversal with fluid infusion should be characterized to define specific point of intervention, 
inform patient decisions on choice decision, referral to higher centers for renal replacement 
therapy and predict outcomes. 
The major delimitation of urinary IL18 comes in its utility to predict AKI in the settings 
of  sepsis  and  multi-organ  dysfunction  (MODS).  Further  research  is  needed to  qualify  and 
quantify its reliability in those situation. This present study is aimed to provide a glimpse of 
future  where  a  combination  of  clinical  and  biomarker  data  should  provide  the  tools  for 
physicians to recognize AKI, inform patients and plan further mode of treatment.
CONCLUSIONS
1. Urinary IL-18 >40pg/ml promises to be a reliable early marker of AKI compared 
with creatinine and urea.( with sensitivity of 87% and specificity of 84%)
2. Urinary IL-18 predates AKI by atleast 24 hours in patients developing acute kidney 
injury (AKI).
3. Urinary IL-18 could serve as morbidity and mortality predictor in various settings of 
AKI.
4. It  should  help  physicians  to  recognize  AKI  early,  inform  patients,  plan  action, 
characterize  the  course  of  disease  and  define  specific  points  of  intervention  and 
predict outcomes.
FURTHER RESEARCH
1. Similar studies can be carried in larger population and different setting (specially in 
patients  undergoing  cardiopulmonary  bypass  where  renal  ischemic  time  can  be 
ascertained after aortic clamping).to test the exact utility of urinary IL18.
2. Relationship of different AKI markers to each other and to establish their capacity to 
predict outcomes.
3. Studies to test the validity of urinary IL-18 as a prognostic marker.
4. Co-relation between serum IL-18 and urinary IL-18.
5. Interleukin  18  levels  in  sepsis  its  reliability  to  predict  multiorgan  dysfunction 
(MODS).
6. Well designed studies to use AKI biomarkers to set standardized criteria for AKI.
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PROFORMA
NAME: AGE/SEX:
TIME OF
BITE: PLACE:
VITALS
TEMPERATURE 
PULSE
BP
ANY CONDITION PREDISPOSING TO AKI
DM / HYPERTENSION / CELLULITIS / SHOCK / 
CAD / SEPSIS / INFECTIONS / INFLAMMATIONS
SPECIFY IF ANY OTHER MEDICAL ILLNESS
BASELINE UREA / CREATININE
USG KUB
R SIZE CMD ECHOES
L SIZE CMD ECHOES
URINE OUTPUT
FOLLOW UP
